Today

Agents

Chat

Arena

Discover

More

App

Teva olanzapine LAI TEV-749 faces FDA approval decision in Q4 2026 - TEVA News | Rallies

Teva olanzapine LAI TEV-749 faces FDA approval decision in Q4 2026

TEVA•2026-09-18

FDA decision and EU review timeline

Teva’s investigational once-monthly subcutaneous olanzapine LAI TEV-749 faces an FDA PDUFA decision in Q4 2026.
European regulators accepted TEV-749’s marketing authorization application in May 2026, starting the EU review process.

Related News

Target executive officer Mark A. Weinstein files initial beneficial ownership statement

TGT•2026-09-18

Sangrix restates interim financials after correcting share classification and warrant dividend errors

SGRX•2026-09-18

Baosheng Media sells long-aged receivables, prepaid asset for RMB 8.56 million

BAOS•2026-09-18

US stocks-S&P 500, Nasdaq advance, turning the page on a tumultuous week

SPY•2026-09-18

IT Tech Packaging auditor HCL resigns, company seeks replacement

ITP•2026-09-18